Los Angeles-based Cedars-Sinai has received more than $20 million to study potential treatments for heart failure and arrhythmogenic cardiomyopathy.
The funding comes from two separate grants — each more than $10 million — from the California Institute for Regenerative Medicine, according to a Dec. 11 news release from Cedars-Sinai.
One grant will support preclinical studies that combine RNA drug TY1 with semaglutide for the treatment of heart failure. The second grant will study a treatment for arrhythmogenic cardiomyopathy, the leading cause of sudden cardiac death in athletes and young people.
Leave a Reply